The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Candida krusei , a Multidrug-Resistant Opportunistic Fungal Pathogen: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005
Open accessAbstract
Candida krusei is well known as a fungal pathogen for patients with hematologic malignancies and for transplant recipients. Using the ARTEMIS Antifungal Surveillance Program database, we describe geographic and temporal trends in the isolation of C. krusei from clinical specimens and the in vitro susceptibilities of 3,448 isolates to voriconazole as determined by CLSI (formerly NCCLS) disk diffusion testing. In addition, we report the in vitro susceptibilities of bloodstream infection isolates of C. krusei to amphotericin B (304 isolates), flucytosine (254 isolates), anidulafungin (121 isolates), caspofungin (300 isolates), and micafungin (102 isolates) as determined by CLSI broth microdilution methods. Geographic differences in isolation were apparent; the highest frequency of isolation was seen for the Czech Republic (7.6%) and the lowest for Indonesia, South Korea, and Thailand (0 to 0.3%). Overall, 83% of isolates were susceptible to voriconazole, ranging from 74.8% in Latin America to 92.3% in North America. C. krusei was most commonly isolated from hematology-oncology services, where only 76.7% of isolates were susceptible to voriconazole. There was no evidence of increasing resistance of C. krusei to voriconazole from 2001 to 2005. Decreased susceptibilities to amphotericin B (MIC at which 90% of isolates were inhibited [MIC 90 ], 4 μg/ml) and flucytosine (MIC 90 , 16 μg/ml) were noted, whereas 100% of isolates were inhibited by ≤2 μg/ml of anidulafungin (MIC 90 , 0.06 μg/ml), micafungin (MIC 90 , 0.12 μg/ml) or caspofungin (MIC 90 , 0.25 μg/ml). C. krusei is an uncommon but multidrug-resistant fungal pathogen. Among the systemically active antifungal agents, the echinocandins appear to be the most active against this important pathogen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 2×
“krusei both confirm and extend previous observations concerning this species (1, 3, 6, 22, 23, 39, 40, 47, 52).”
BackgroundResultSelf-citationGuidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard
Rex, J. H., & Clinical (2008) · Clinical and Laboratory Standards Institute eBooks · Cited by 1,052
Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937
Self-citationSlavin, M. A., Osborne, B., Adams, R., Levenstein, M. J., Schoch, H. G., Feldman, A. R., Meyers, J. D., & Bowden, R. A. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1545 · Cited by 820
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance
Hong Nguyen, M., Peacock, J. E., Morris, A. J., Tanner, D. C., Nguyen, M. L., Snydman, D. R., Wagener, M. M., Rinaldi, M. G., & Yu, V. L. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(95)00010-0 · Cited by 758
Self-citationThe Epidemiology of Hematogenous Candidiasis Caused by Different Candida Species
Abi‐Said, D., Anaissie, E., Uzun, O., Raad, I., Pinzcowski, H., & Vartivarian, S. (1997) · Clinical Infectious Diseases · doi:10.1086/513663 · Cited by 755 · cited 1×
“Candida krusei has been recognized as a potentially multidrug-resistant (MDR) fungal pathogen, due to its intrinsic fluconazole resistance combined with reports of decreased susceptibility to both flucytosine and amphotericin B (1, 2, 3, 6, 20, 22, 23, 26, 37, 39, 47, 61).”
BackgroundPfaller, M. A., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.10.4419-4431.2004 · Cited by 694
Self-citationImportance of Candida Species Other than C. albicans as Pathogens in Oncology Patients
Wingard, J. R. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.1.115 · Cited by 542 · cited 1×
“Whether this observation is a direct result of fluconazole administration remains controversial, since others have reported infections due to this species before the introduction of fluconazole (14, 22, 60).”
Background
Cited by
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Self-citationAzole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodloff, A., Fu, W., & Ling, T. A. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02117-09 · Cited by 718
Self-citationEfflux-Mediated Antifungal Drug Resistance
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., & Monk, B. C. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-08 · Cited by 608
Fluconazole resistance in Candida species: a current perspective
Berkow, E., & Lockhart, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s118892 · Cited by 542
Pfaller, M. A., Andes, D. R., Diekema, D. J., Horn, D. L., Reboli, A. C., Rotstein, C., Franks, B., & Azie, N. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101510 · Cited by 396
Self-citationAntifungal drug resistance among Candida species: mechanisms and clinical impact
Sanguinetti, M., Posteraro, B., & Lass‐Flörl, C. (2015) · Mycoses · doi:10.1111/myc.12330 · Cited by 394
Current Concepts in Antifungal Pharmacology
Lewis, R. E. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0247 · Cited by 377
Nosocomial Fungal Infections: Epidemiology, Infection Control, and Prevention
Alangaden, G. J. (2011) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2010.11.003 · Cited by 337
Roscetto, E., Contursi, P., Vollaro, A., Fusco, S., Notomista, E., & Catania, M. R. (2018) · Scientific Reports · doi:10.1038/s41598-018-35530-0 · Cited by 272
Reducing infections through nanotechnology and nanoparticles
Webster, T. J., & Taylor (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s22021 · Cited by 267
Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults
Sandison, T., Ong, V., Lee, J., & Thye, D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01627-16 · Cited by 161
Lamping, E., Ranchod, A., Nakamura, K., Tyndall, J. D. A., Niimi, K., Holmes, A. R., Niimi, M., & Cannon, R. D. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01095-08 · Cited by 100
Mining the oral mycobiome: Methods, components, and meaning
Diaz, P. I., Hong, B.-Y., Dupuy, A. K., & Strausbaugh, L. D. (2017) · Virulence · doi:10.1080/21505594.2016.1252015 · Cited by 87
An Antifungal Benzimidazole Derivative Inhibits Ergosterol Biosynthesis and Reveals Novel Sterols
Keller, P., Müller, C., Engelhardt, I., Hiller, E., Lemuth, K., Eickhoff, H., Wiesmüller, K.-H., Burger-Kentischer, A., Bracher, F., & Rupp, S. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00640-15 · Cited by 50
Mohammad, H., Elghazawy, N. H., Eldesouky, H. E., Hegazy, Y. A., Younis, W., Avrimova, L., Hazbun, T., Arafa, R. K., & Seleem, M. N. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00215 · Cited by 29
Shokohi, T., Aslani, N., Ahangarkani, F., Meyabadi, M. F., Hagen, F., Meis, J. F., Boekhout, T., Kolecka, A., & Badali, H. (2018) · Microbial Pathogenesis · doi:10.1016/j.micpath.2017.12.069 · Cited by 11
Metadata
- Authors
- Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Nagy, E., Dobiasova, S., Rinaldi, M., Barton, R., Veselov, A., & the Global Antifungal Surveillance Group
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2008-02
- Volume
- 46
- Issue
- 2
- Pages
- 515-521
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- OpenAlex
- W2160721469
- Cited by
- 259
- References
- 62
- FWCI
- 8.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.